Compare Amphastar Pharmaceuticals Inc (AMPH) vs Synchrony Financial (SYF) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Synchrony Financial — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Synchrony Financial trades at $72.44 (market cap $24.37B). The key difference: Synchrony Financial is far larger — about 29.5× Amphastar Pharmaceuticals Inc's market cap, and Synchrony Financial pays a 1.66% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | SYF | |
|---|---|---|
Market Cap | $826.08M | $24.37B |
Sector | Health | Financials |
52-Week High | $30.81 | $88.47 |
52-Week Low | $16.87 | $63.78 |
Enterprise Value | $1.22B | — |
Dividend Yield | — | 1.66% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Synchrony Financial (SYF) trades at $72.44, up 1.22% with strong fundamental metrics including a low P/E of 7.5 and robust ROE of 22.98%. The company has consistently beaten earnings expectations in recent quarters, with Q2 2026 results expected July 21. Technical indicators show bearish momentum despite neutral oscillators, with key support at $69 and resistance at $73. Recent corporate developments include executive leadership changes and expansion of CareCredit partnerships.
SYF presents a compelling value opportunity with attractive valuation multiples and consistent earnings performance. The stock offers 19% upside to consensus price target of $86, supported by strong analyst sentiment (62.5% buy ratings). Key risks include economic sensitivity to consumer credit and inflationary pressures. The upcoming Q2 earnings report will be crucial for confirming the company's growth trajectory amid current market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
